Ekso Bionics (EKSO) Stock Forecast & Price Target

$0.63 -0.09 (-11.99%)

(As of 12/18/2024 05:45 PM ET)

Ekso Bionics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 2 Analyst Ratings

Sell
0

Hold
0

Buy
2

Based on 2 Wall Street analysts who have issued ratings for Ekso Bionics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 2 analysts, 2 have given a buy rating for EKSO.

Consensus Price Target

$5.50
771.63% Upside

According to the 2 analysts' twelve-month price targets for Ekso Bionics, the average price target is $5.50. The highest price target for EKSO is $9.00, while the lowest price target for EKSO is $2.00. The average price target represents a forecasted upside of 771.63% from the current price of $0.63.

Get the Latest News and Ratings for EKSO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ekso Bionics and its competitors.

EKSO Analyst Ratings Over Time

Type	Current Forecast 12/20/23 to 12/19/24	1 Month Ago 11/20/23 to 11/19/24	3 Months Ago 9/21/23 to 9/20/24	1 Year Ago 12/20/22 to 12/20/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.50	$5.50	$6.25	$9.00
Forecasted Upside	771.63% Upside	677.93% Upside	416.53% Upside	435.71% Upside
Consensus Rating	Buy	Buy	Buy	Buy

I want to send you my Cash Calendar (Ad)

This Calendar reveals the EXACT dates that — if everything goes right — anyone can target cash payouts of $125, $415, and even $1,665. (With just a $1,000 starting stake!) Granted, there were smaller wins and those that did not work out and we cannot promise future returns or against losses, but these payouts don’t require any special knowledge or skills. Anyone can set them up with just three clicks in their brokerage account. And the money can be deposited in their account the very next morning after opening the trade. Again, I want to send this Cash Calendar to you completely FREE. All you have to do is join me for my free Cash Calendar training right here. You don’t want to miss this. There is a very special bonus surprise for everyone who attends.

Reserve your seat.

EKSO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EKSO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ekso Bionics Stock vs. The Competition

Type	Ekso Bionics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	771.63% Upside	28,417.88% Upside	15.36% Upside
News Sentiment Rating	Neutral News See Recent EKSO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/29/2024	Lake Street Capital 2 of 5 stars	B. Haynor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$2.50 ➝ $2.00	+98.18%
10/29/2024	HC Wainwright 2 of 5 stars		Lower Target	Buy ➝ Buy	$10.00 ➝ $9.00	+696.45%
4/28/2023	500.com 0 of 5 stars		Reiterated Rating	Reiterates

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:22 AM ET.

EKSO Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Ekso Bionics is $5.50, with a high forecast of $9.00 and a low forecast of $2.00.
: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EKSO shares.
: According to analysts, Ekso Bionics's stock has a predicted upside of 771.63% based on their 12-month stock forecasts.
: Ekso Bionics has been rated by research analysts at HC Wainwright, and Lake Street Capital in the past 90 days.
: Analysts like Ekso Bionics more than other "medical" companies. The consensus rating for Ekso Bionics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EKSO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NASDAQ:EKSO) was last updated on 12/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ekso Bionics (EKSO) Stock Forecast & Price Target